retatrutide approved by fda (RETA) Trial of next-gen weight-loss drug

The enforcement focus is on controlled substances, large quantities suggesting resale, and counterfeit products

"Weight Loss Efficacy and Cardiovascular Benefits in Phase 2 Metabolic Therapy Trials." New England Journal of Obesity Research, vol

Patients should also seek evaluation if they experience numbness, tingling, or color changes in fingers and toes (particularly white, blue, or red discoloration), which could indicate peripheral vascular issues or Raynaud's phenomenon rather than simple cold sensitivity

The most common are gastrointestinal issues such as nausea, diarrhea and constipation

This dose produces meaningful weight loss for many people, though some will eventually need higher doses for optimal results